{"id":"NCT01945294","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","officialTitle":"A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy With MK-3034 (SCH 503034)/Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects With Chronic HCV Genotype 1 in Asia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-10","primaryCompletion":"2015-08-05","completion":"2015-11-04","firstPosted":"2013-09-18","resultsPosted":"2016-11-23","lastUpdate":"2018-07-12"},"enrollment":257,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Boceprevir","otherNames":["MK-3034"]},{"type":"BIOLOGICAL","name":"Peg-interferon alfa-2b","otherNames":["PegIntron"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Rebetol"]}],"arms":[{"label":"Arm 1: 16-week Treatment Arm","type":"EXPERIMENTAL"},{"label":"Arm 2: 28-week Treatment Arm","type":"EXPERIMENTAL"},{"label":"Arm 3: 48-week Treatment Arm","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to estimate the difference in the efficacy between a 16-week treatment regimen of boceprevir (BOC) in combination with peg-intron alpha 2b (P) plus ribavirin (R) (BOC + PR) and a 28-week treatment regimen of BOC + PR in previously untreated participants with chronic hepatitis C (CHC) genotype 1 in Asia who achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA).","primaryOutcome":{"measure":"Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]","timeFrame":"Follow-up Week (FW) 12 (up to 40 weeks)","effectByArm":[{"arm":"Arm 1: 16-week Treatment Arm","deltaMin":70.6,"sd":null},{"arm":"Arm 2: 28-week Treatment Arm","deltaMin":81.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":102},"commonTop":["Anaemia","Alopecia","Pyrexia","Decreased appetite","Myalgia"]}}